Rather than chasing generative AI, pharma executives can focus their AI & machine learning (ML) strategies for drug development on investing in and deploying connected sensors to reduce costs & improve patient outcomes.
The topic of generative AI has taken the world, pharma included, by storm — however, the field is relatively new and untested in the realm of pharmaceutical research, drug discovery, and drug development. Despite this, many pharma companies are leaning into these unknowns across the R&D lifecycle instead of doubling down on existing AI & ML-powered innovations that have proven effective and reliable repeatedly in drug development: digital biomarkers.
In August 2023, the European Medicines Agency formally qualified the first DHT-derived digital primary endpoint with a new stride-velocity measure for drug development in Duchenne Muscular Dystrophy as an alternative to traditional walking tests. The benefits of the digital endpoint — continuous monitoring over long periods of time, reduced reliance on patient motivation, and more — drive increased likelihood of approval beyond the capabilities of the 6-minute walk test. There is over a decade of validated research on deployment of digital biomarkers in life sciences, with proven return on investment to reduce trial cost and de-risk trial success, and these efforts are getting more attention and investment than ever before.
We’re seeing support for this innovation from regulatory bodies within the U.S. as well. This past summer, the FDA published a paper on AI & ML for Drug Development, with case studies from discovery through to development, commercial, and manufacturing. While generative AI systems like ChatGPT have recently gotten the lion’s share of attention, the FDA chose to focus its paper largely on biomarkers measured by digital health technologies (DHTs), such as connected sensors, which nearly all already use AI & ML to analyze and interpret data.
Regulatory support goes beyond drug discovery — the new FDA paper outlines six opportunity areas for leveraging AI & ML for drug development, several of which rely heavily on DHTs. These technologies can help improve clinical trial quality by supporting sensor-derived data collection and analysis, as well as better detection of drug safety and efficacy by monitoring patient symptoms in real-time.
The use of DHTs has the potential to improve trial diversity, an especially important consideration in the wake of the new regulatory mandates and legislation from the DEPICT Act and FDORA which are requiring diversity action plans to drive down trial costs from reduced sample size, reduced trial duration, and increased patient retention and improved sustainability.
- At the JP Morgan Healthcare conference in January 2023, Roche CFO Alan Hippe cited a 70% reduction in sample size and half the required trial duration in their PASADENA study by using a novel digital endpoint.
- In June 2023, the FDA endorsed a digital outcome measure of physical activity as a primary endpoint in Bellerophon’s pivotal trial using wearable data, showing that data from the sensor could be used to reduce the trial’s sample size by more than 50%.
- Astrazeneca’s CRESCENDO trial is currently leveraging a smart spirometer and a cloud-based AI solution for quality control in data collection for both primary and secondary endpoints, predicting to cut treatment duration in half and reduce overall trial duration by up to 15%.
Compared to digital biomarkers, the field of generative AI is new and unproven for pharma, an industry where millions of lives and billions of dollars depend on scientific evidence for proof of efficacy and safety. Despite this, we’re seeing pharma lean into the more novel, unknowns of AI, instead of doubling down on the existing biomarker innovation that has proven effective and reliable.
In June, Sanofi announced that they are going “all in” on artificial intelligence and data science, and called out a number of partnerships in areas such as drug discovery. Beyond drug discovery, there is an extended opportunity to expand investment strategies into drug development. Objectives of trial sponsors are to de-risk trial success and FDA approval, while also showing influence in the industry by investing in innovation and new technology to accelerate their operations. While the two may seem contradictory, investment in evidence-based methods that leverage AI & ML is an easy win — DHTs and data models have been using AI & ML for more than ten years, with thousands of trials conducted to safeguard their investment.
With data curated by the Atlas platform for precision measurement, we know that more than 130 pharma and biotech companies have invested in DHTs. Metrics range from walking speed and blood pressure to sleep quality and cognition, with over 1,300 AI-powered digital biomarkers deployed in clinical trials in the past 15 years.
Source: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products; Atlas
As pharma executives craft their AI & ML strategies, they could explore new tools like generative AI, or they could choose to invest in digital biomarkers that have been consistently validated and are well-known for safe and effective clinical trials. Prioritizing digital biomarkers is no longer a nice-to-have, but rather a tried and true investment that already leverages innovative solutions within AI & ML to improve patient outcomes, faster.
Blog authored by Abby DeVito, Sr. Director, Go-to-Market, ICON. Originally written for HumanFirst, a company acquired by Icon in january 2024.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel